Skip to main content
. 2025 May 6;8:100171. doi: 10.1016/j.esmogo.2025.100171

Figure 3.

Figure 3

Kaplan–Meier estimates for immune checkpoint inhibitor (ICI)-based therapy according to the early tumor shrinkage (ETS) status. (A) Progression-free survival (PFS) and (B) overall survival (OS) in ICI + chemotherapy (chemo). (C) PFS and (D) OS in nivolumab + ipilimumab (nivo + ipi). CI, confidence interval; NR; not reached.